Novel Adjuvant Discovery in Vaccine Therapy

疫苗治疗中新佐剂的发现

• 批准号: 8298167
• 负责人: SAMUEL J DANISHEFSKY
• 金额: $ 87.17万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-06-01 至 2014-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8298167
• 关键词: Acute; Address; Adjuvant; Advanced Malignant Neoplasm; Affinity Chromatography; Animals; Antigens; Antiviral Agents; Applications Grants; Attenuated; Behavior; Biochemical; Biodistribution; Biological; Biological Factors; Cancer Vaccine Related Development; Cancer Vaccines; Centers for Disease Control and Prevention (U.S.); Chemicals; Chemosensitization; Clinical; Communicable Diseases; Complex; Development; Discipline; Dose; Dose-Limiting; Drug Formulations; Drug Kinetics; Enzyme-Linked Immunosorbent Assay; Epidemic; Evaluation; Generations; Glycolipids; Goals; Harvest; Image; Imaging technology; Immune; Immune response; Immunization; Immunologic Adjuvants; Immunologics; Impotence; In Vitro; Investigation; Keyhole Limpet Hemocyanin; Laboratories; Lead; Malignant Neoplasms; Methodology; Molecular; Mucin-1 Staining Method; Mus; Organ; Patients; Peptides; Pharmacodynamics; Positron-Emission Tomography; Preparation; QS21; Radio; Radiochemistry; Radiolabeled; Research; Resistance; Role; Safety; Saponin; Saponins; Screening procedure; Structure; Technology; Time; Tissues; Toxic effect; Vaccine Adjuvant; Vaccine Clinical Trial; Vaccine Therapy; Vaccines; Variant; analog; authority; cellular targeting; chemical synthesis; combat; cytokine; design; functional group; immunogenic; improved; in vivo; insight; interest; novel; novel therapeutics; pre-clinical; preclinical evaluation; preclinical study; programs; public health relevance; radiotracer; response; success; sugar; tumor immunology; vaccine development; vaccinology

DESCRIPTION (provided by applicant): The development of vaccines to combat vaccine resistant cancers and infectious diseases has relied significantly on constructs employing subunit antigens. While the use of defined molecular antigens offers advantages in terms of safety and precision in immune response targeting, they are typically less immunogenic. Often, these vaccine formulations require an adjuvant, a substance that potentiates immune response. The critical roles of vaccine adjuvants lie in their ability to (1) enable the use of otherwise impotent antigens, (2) extend the benefits of vaccines to poor responders (e.g., older or immune-compromised patients), and (3) effect "dose-sparing" of rare and expensive antigens in short supply (e.g., in an epidemic). The natural product saponin QS-21 is the adjuvant of choice in numerous promising antitumor and antiviral vaccine clinical trials, despite liabilities associated with toxicity, chemical instability, and lack of availability in pure form. This grant application comprises a unique multi-disciplinary approach toward the preparation, discovery, evaluation, and understanding of potent adjuvant molecules essential in the development of vaccines for cancer and infectious diseases. The Specific Aims of this research program will involve: (1) the development of novel and efficient strategies for the chemical synthesis of designed non-natural structural variants of the saponin QS-21 possessing improved activity and stability with attenuated toxicity; (2) the evaluation of these novel compounds in mice to assess their ability to potentiate immune response, as well as their specific toxicity profiles; and (3) to employ small animal radio-imaging technologies, immunohistology, cytokine profiling, and affinity chromatography to gain insight into the adjuvant's as yet unknown mechanism of action. These efforts will address fundamental chemical and immunological questions associated with this extremely complex class of adjuvants, and holds the promise of yielding novel therapeutics in the vaccine arena. PUBLIC HEALTH RELEVANCE: The success of antitumor and antiviral vaccines often requires the use of an adjuvant, a substance that is itself not necessarily immunogenic, but significantly enhances the immune response of a patient to a co- administered antigen. This grant application comprises a unique multi-disciplinary approach toward the preparation, discovery, evaluation, and understanding of potent adjuvant molecules essential in the development of vaccines for cancer and infectious diseases. These efforts will address fundamental chemical and immunological questions central to immune response potentiation, and holds the promise of yielding novel therapeutics in the vaccine arena.

描述（由申请人提供）：用于对抗疫苗耐药癌症和传染病的疫苗的开发在很大程度上依赖于采用亚单位抗原的构建。虽然使用确定的分子抗原在免疫应答靶向方面提供了安全性和准确性方面的优势，但它们通常免疫原性较低。通常，这些疫苗配方需要一种佐剂，一种增强免疫反应的物质。疫苗佐剂的关键作用在于它们能够(1)使使用原本无效的抗原成为可能，(2)将疫苗的益处扩展到应答不良的患者（例如，老年人或免疫功能低下的患者），以及(3)对供应短缺的稀有和昂贵抗原（例如，在流行病中）实现“剂量节约”。天然产物皂苷QS-21是许多有前途的抗肿瘤和抗病毒疫苗临床试验的首选佐剂，尽管存在毒性、化学不稳定性和缺乏纯形式的可用性等缺点。这项拨款申请包括一个独特的多学科方法，用于制备、发现、评估和理解在癌症和传染病疫苗开发中必不可少的强效佐剂分子。本研究计划的具体目标将包括：(1)开发新的和有效的策略，用于化学合成设计的皂苷QS-21的非天然结构变体，这些变体具有更高的活性和稳定性，并且毒性较弱；(2)在小鼠中评估这些新化合物，以评估它们增强免疫反应的能力，以及它们的特定毒性谱；(3)利用小动物放射成像技术、免疫组织学、细胞因子谱和亲和层析来深入了解佐剂的未知作用机制。这些努力将解决与这类极其复杂的佐剂相关的基本化学和免疫学问题，并有望在疫苗领域产生新的治疗方法。